Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

14.00 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10
Open 14.00
Bid (Size) 14.55 (5)
Ask (Size) 14.80 (10)
Prev. Close 14.00
Today's Range 14.00 - 14.00
52wk Range 9.240 - 28.20
Shares Outstanding 84,076,737
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virt
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and... 
From Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and... 
From Business Wire News Releases

Performance

YTD
-28.72%
-28.72%
1 Month
-2.57%
-2.57%
3 Month
-15.15%
-15.15%
6 Month
-39.45%
-39.45%
1 Year
+33.97%
+33.97%

More News

Read More
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Business Wire News Releases
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
From Business Wire News Releases
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
From Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Business Wire News Releases
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
From Business Wire News Releases
Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients
Tags Biotech Small Cap News
From Benzinga
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
From Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Business Wire News Releases
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.